NovoCure Limited (NVCR) Free cash flow 2017–2026
NovoCure Limited (NVCR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$75.7MFY2026 · since FY2017: -$113.3M → -$75.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$75.7M | -9.3% |
| FY2025 | -$69.2M | +31.1% |
| FY2024 | -$100.4M | -1165.0% |
| FY2023 | $9.4M | -83.9% |
| FY2022 | $58.6M | -30.4% |
| FY2021 | $84.2M | +421.7% |
| FY2020 | $16.1M | +288.1% |
| FY2019 | -$8.6M | +78.8% |
| FY2018 | -$40.5M | +64.2% |
| FY2017 | -$113.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NVCR financial trends
NVCR RevenueNVCR Net incomeNVCR Net marginNVCR Gross profitNVCR Gross marginNVCR Operating incomeNVCR Operating marginNVCR Operating cash flowNVCR Capital expendituresNVCR Return on equityNVCR Stock buybacksNVCR Dividends paidNVCR Total assetsNVCR Total liabilitiesNVCR Shareholders’ equityNVCR overview →